Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

11/08/2012 | 05:25pm US/Eastern
Recommend:
0

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.

Sincerely,

/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer
William.Coote@taro.com


© Business Wire 2012
Recommend :
0
React to this article
Latest news on TARO PHARMACEUTICAL INDUST
08/07 TARO PHARMACEUTICAL : Provides Results for Quarter Ended June 2014
08/04 TARO PHARMACEUTICAL : to Announce Results for Quarter Ended June 30, 2014
07/08 TARO PHARMACEUTICAL : Annual Report For Fiscal Year Ended March 31, 2014 on Form..
06/30DJIndia Shares Rise Strongly, Bringing Year-To-Date Gains to 20%
06/10 TARO PHARMACEUTICAL : Dosing Initiation, Conferences Participation, Trial Result..
05/27 TARO PHARMACEUTICAL : Provides Results for Year Ended March 31, 2014
05/19 TARO PHARMACEUTICAL : to Announce Results for Quarter and Year Ended March 31, 2..
03/27 TARO PHARMACEUTICAL : Announces Results of Its Extraordinary General Meeting of ..
03/20 TARO PHARMACEUTICAL : BlueMountain Capital Management, LLC : Urges Minority Shar..
03/18 TARO PHARMACEUTICAL : Glass Lewis Recommends Taro Pharmaceutical Shareholders Vo..
Advertisement
Chart
Duration : Period :
Taro Pharmaceutical Indust Technical Analysis Chart | TARO | IL0010827181 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF